Nyxoah SA Ordinary Shares NYXH

Nyxoah SA is a health-technology company focused on the development and commercialization of solutions and services to treat sleep-disordered breathing conditions. The company's solution platform is based on the Genio system, a CE-Mark validated, user-centered, bilateral neurostimulation therapy to treat moderate to severe Obstructive Sleep Apnea (OSA), the common sleep disordered breathing condition that is associated with increased mortality risk and comorbidities including cardiovascular diseases, depression and stroke.

• Zacks Investment Research 8 sept

  Nyxoah Stock Down Despite First Genio Implant in U.S. BREATHE Trial

  Nyxoah (NYXH) initiated its U.S. post-approval BREATHE study with the first patient implanted using the Genio system for obstructive sleep apnea treatment. The study will enroll up to 229 patients across 25 U.S. centers over five years to generate real-world evidence supporting physician adoption and payer reimbursement. Despite the milestone, NYXH shares fell approximately 8% following the announcement.

  

• GlobeNewswire Inc. 7 sept

  Nyxoah Annonce l’Implantation du Premier Patient dans BREATHE, l’Étude Post-Approbation Américaine du Système Genio®

  Nyxoah announced the first patient implantation in BREATHE, a post-approval U.S. study of its Genio® system for obstructive sleep apnea treatment. The study will implant up to 229 patients across 25 U.S. centers over five years to evaluate long-term safety and efficacy in real-world clinical practice. The first procedure was performed by Dr. Rolando Molina at South Florida ENT Associates.

  

• GlobeNewswire Inc. 7 sept

  Nyxoah Announces First Patient Implanted in BREATHE, the U.S. Post-Approval Study of the Genio® System

  Nyxoah announced the first patient implantation in BREATHE, a U.S. post-approval study of its Genio system for obstructive sleep apnea treatment. The multicenter study will implant up to 229 patients across 25 U.S. centers and follow them for up to five years to evaluate long-term safety and effectiveness of the bilateral hypoglossal nerve stimulation therapy in real-world clinical practice.

  

• GlobeNewswire Inc. 19 jun

  Invitation à assister à l'assemblée générale extraordinaire des actionnaires de la Société qui se tiendra le 9 juillet 2026

  Nyxoah has secured $15 million in non-dilutive debt funding from the European Investment Bank, complementing the company's June equity raise and bringing total capital raised to $110 million. The company is also holding an extraordinary general shareholders' meeting on July 9, 2026, to renew authorization for capital increases.

  

• GlobeNewswire Inc. 19 jun

  Invitation to attend the extraordinary shareholders’ meeting of the Company to be held on July 9, 2026

  Nyxoah SA (Euronext Brussels/Nasdaq: NYXH) has announced an extraordinary shareholders' meeting scheduled for July 9, 2026, to vote on renewing the board of directors' authorization to increase the company's share capital. The meeting will allow shareholders to participate in-person or via video conference, with voting available through proxy or mail.